Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.66 |
| ▸ | TNKS | O95271 | 3/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.56 |
| ▸ | GUSB | P08236 | 1/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117076 | 0.88 | HDAC6 (0.77) | HDAC6HDAC8TNKSTNKS2GUSB | |
| SCHEMBL2611485 | 0.85 | HDAC6 (0.62) | HDAC6HDAC8TNKSGUSBHDAC3 | |
| SCHEMBL2120492 | 0.85 | HDAC6 (0.62) | HDAC6HDAC8TNKSTNKS2GUSB | |
| SCHEMBL4550117 | 0.85 | HDAC6 (0.65) | HDAC6HDAC8TNKSTNKS2PARP2 | |
| SCHEMBL17942020 | 0.84 | TNKS (0.67) | HDAC6HDAC8TNKSTNKS2GUSB | |
| SCHEMBL2115413 | 0.83 | HDAC6 (0.67) | HDAC6HDAC8TNKSGUSBHDAC3 | |
| SCHEMBL18229590 | 0.81 | HDAC6 (0.79) | HDAC6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL2116074 | 0.81 | GUSB (0.61) | HDAC6HDAC8GUSBHDAC3HDAC1 | |
| SCHEMBL2117471 | 0.80 | MAPT (0.60) | HDAC6HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL2118741 | 0.78 | HDAC6 (0.57) | HDAC6HDAC8HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC8 14/4885TNKS 829/4885 |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC8 14/4885TNKS 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.